Novartis Jury Awards $10.45 Million for Drug, Lawyer Says

Novartis Pharmaceuticals Corp. (NVS) was found liable by a federal jury for jawbone damage in a woman who took the drug Zometa, and she was awarded $10.45 million, a lawyer for the plaintiff said.

A jury in Central Islip, New York, returned the verdict this afternoon, several hours after they began deliberations in the case, said John Vecchione, a lawyer for plaintiff Barbara Davids.

The verdict, which couldn’t be immediately confirmed in court records, is the second-largest among similar cases over Zometa, Vecchione said. It is the fourth win for plaintiffs out of eight Zometa-related jawbone cases that have gone to trial, he said. The jury in the Davids case awarded $450,000 in compensatory damages and $10 million in punitive damages, he said.

“What’s happening is these juries are seeing very bad behavior,” Vecchione said in a phone interview. “These juries are finding this evidence particularly egregious.”

A New York-based spokeswoman for Basel, Switzerland-based Novartis, Julie Masow, said in an e-mail statement that the company is reviewing its options for appeal.

“We are disappointed and disagree with the jury’s verdict,” she said.

2006 Complaint

In a complaint filed in February 2006, Davids alleged that she developed osteonecrosis, or bone death, in her jaw after taking Zometa, a drug she had been prescribed as part of her treatment for breast cancer. Zometa, a bisphosphonate, is a treatment for bone complications that can result from cancer, according to a Novartis website.

During the trial, which began Oct. 2, the attorneys for Davids showed the jurors a May 2003 e-mail in which a Novartis marketing employee described a proposed report linking Zometa to jawbone complications as “quite damaging.” In another e-mail from May 2003 used as evidence in the trial, the employee outlined a strategy to colleagues for “next steps,” including a public relations effort.

“In summary: we’ll try to avoid that the paper is ever published; we will be ready to react in case it gets published,” the employee said in the e-mail. The e-mails were provided to Bloomberg News by Vecchione.

The largest verdict in Zometa-related jawbone osteonecrosis cases was $12.8 million, awarded to a North Carolina woman’s family in November 2010. The award was later reduced to about $1.1 million under state law.

The case is Davids v. Novartis, 2:06-cv-431, U.S. District Court, Eastern District of New York (Central Islip).

To contact the reporter on this story: Christie Smythe in New York at

To contact the editor responsible for this story: Michael Hytha at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.